(Q34268760)

1 August 2017

title

Maintenance therapies in bipolar disorders (English)

1 reference

1 August 2017

2

Mark A Frye

1 reference

1 August 2017

Michael Gitlin

1

1 reference

1 August 2017

publication date

1 May 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

14 Suppl 2

1 reference

1 August 2017

page(s)

51-65

1 reference

Relapse and impairment in bipolar disorder

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

The long-term natural history of the weekly symptomatic status of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Morbidity in 303 first-episode bipolar I disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Improving the design of maintenance studies for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Clinical practice recommendations for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Psychotropic drug prescription patterns among patients with bipolar I disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Is lithium in a class of its own? A brief profile of its clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Lithium specificity in bipolar illness: a classic agent for the classic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Maintenance efficacy of divalproex in the prevention of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Prophylactic effect of phenytoin in bipolar disorder: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Use of topiramate in treatment-resistant bipolar spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Open-label adjunctive topiramate in the treatment of unstable bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Lithium and the kidney: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Renal failure occurs in chronic lithium treatment but is uncommon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Side effects of valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Reproductive function and risk for PCOS in women treated for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Oxcarbazepine in bipolar disorder: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Ziprasidone in the management of schizophrenia : the QT interval issue in context

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

Adjunctive psychotherapy for bipolar disorder: state of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2012.00992.X

10.1111/J.1399-5618.2012.00992.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference